139 related articles for article (PubMed ID: 21916635)
1. "Pay for delay" settlements of disputes over pharmaceutical patents.
Kesselheim AS; Murtagh L; Mello MM
N Engl J Med; 2011 Oct; 365(15):1439-45. PubMed ID: 21916635
[No Abstract] [Full Text] [Related]
2. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
3. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
4. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
5. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
Yvon AM
Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
[No Abstract] [Full Text] [Related]
6. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
7. Antitrust issues in the settlement of pharmaceutical patent disputes, Part II.
Leary TB
J Health Law; 2001; 34(4):657-71. PubMed ID: 11833411
[TBL] [Abstract][Full Text] [Related]
8. The wake of FTC v. Actavis: practical implications on the pharmaceutical industry.
Ritter M; Tempesta J; Ragusa P
Pharm Pat Anal; 2014 Jul; 3(4):345-7. PubMed ID: 25291307
[No Abstract] [Full Text] [Related]
9. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
Brockmeier MS
Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
[No Abstract] [Full Text] [Related]
10. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
Srivastava D
Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
[No Abstract] [Full Text] [Related]
11. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
12. US policy may encourage counterfeit drugs.
Bouchie A
Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
[No Abstract] [Full Text] [Related]
13. Are reverse payments and pay-for-delay settlements business as usual or an anticompetitive practice?
Shah S; Silva MA; Malloy MJ
Nat Biotechnol; 2016 Jul; 34(7):716-9. PubMed ID: 27404880
[No Abstract] [Full Text] [Related]
14. The FTC v. Actavis roadmap: a guide to properly applying the rule of reason standard in reverse payment cases.
Sharkey N
J Leg Med; 2014; 35(3):445-66. PubMed ID: 25207633
[No Abstract] [Full Text] [Related]
15. Delaying generic competition--corporate payoffs and the future of Plavix.
Shuchman M
N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
[No Abstract] [Full Text] [Related]
16. The Role of Regulatory Agencies and Intellectual Property: Part II.
Noonan KE
Cold Spring Harb Perspect Med; 2015 Mar; 5(7):a020834. PubMed ID: 25775920
[TBL] [Abstract][Full Text] [Related]
17. Generic drugs: the stalling game.
Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
[TBL] [Abstract][Full Text] [Related]
18. Championing consumers. Leibowitz talks of challenging patent agreements, role of antitrust enforcement. Interview by Joe Carlson.
Leibowitz J
Mod Healthc; 2013 Feb; 43(6):18-9. PubMed ID: 23487902
[No Abstract] [Full Text] [Related]
19. Gene therapy and the 14th century Karelians.
Jex EA; Inglefield DL; Christini MA
Nat Biotechnol; 1997 Apr; 15(4):299. PubMed ID: 9094109
[No Abstract] [Full Text] [Related]
20. Federal Trade Commission antitrust enforcement in the dental profession.
Ragan MR
J Law Ethics Dent; 1990; 3():5-11. PubMed ID: 2098529
[No Abstract] [Full Text] [Related]
[Next] [New Search]
